The Column Group is a leading venture capital firm dedicated to creating the next generation of biotechnology companies. The Column group will invest in 10-12 disease-focused drug discovery companies per fund, each with the potential to become a leader in their respective fields. These companies will be strongly supported by the unique and complementary skill sets of our team, which includes prominent authorities in the scientific, operational and financial arenas. Typically, The Column Group will commit $15M to $30M per company, fostering their growth from seed and early stage to later stages of development. The Column Group seeks to partner with exceptional scientific founders, entrepreneurs, executives and investment organizations that share our vision for building the next generation of drug discovery and development companies.
Founded in 2002, 5AM Ventures actively invests in next-generation life science companies. The firm recently closed 5AM Ventures IV, L.P., a $250 million venture capital fund. With over $685 million under management, 5AM has invested in 40 early-stage companies and its successful exits include Alexza Pharmaceuticals (Nasdaq: ALXA), Envoy Therapeutics (sold to Takeda), Ilypsa (sold to Amgen), Incline Therapeutics (sold to The Medicines Company), KaloBios (Nasdaq: KBIO), Marcadia (sold to Roche), Miikana Therapeutics (sold to EntreMed), Panomics (sold to Affymetrix), Pearl Therapeutics (sold to AstraZeneca), Relypsa (Nasdaq: RLYP), Semprus (sold to Teleflex) and Synosia Therapeutics (sold to Biotie Therapies).
OrbiMed is a leading investment firm dedicated exclusively to the healthcare sector, with over $8 billion in assets under management. OrbiMed invests globally across the spectrum of healthcare companies, from venture capital startups to large multinational companies. OrbiMed’s team of more than 80 employees manages a series of private equity funds, public equity funds, royalty/debt funds and other investment vehicles. OrbiMed maintains its headquarters in New York City, with additional offices in San Francisco, Shanghai, Mumbai and Herzliya. As one of the largest investment firms dedicated to the healthcare sector, OrbiMed seeks to be a capital provider of choice, bringing the global resources required to be an exceptional long-term partner for building world-class healthcare companies.
Third Rock Ventures is a leading health care venture firm focused on investing and launching companies that make a difference in people’s lives. The Third Rock team has a unique vision for ideating and building transformative healthcare companies. Working closely with our strategic partners and entrepreneurs, Third Rock has an extensive track record for managing the value creation path to deliver exceptional performance.